Figure 2.

Frequency of individual treatment-attribute evaluation across ten patient-preference studies identified by literature review.

Notes: ^aVariously across studies: MUP, SUP, vial and syringe, or autoinjector. ^bInjection preparation associated with vial and syringe, SUP, MUP, and autoinjector (Qin et al).^{15,23 c}In one study, nausea was described as “frequency of GI AEs,” but described by levels of nausea incidence only (Poon et al).^{17 d}Common AEs are a combination of nausea, vomiting, diarrhea, and injection-site nodules (Qin et al).¹⁵,²³

Abbreviations: AE, adverse event; BG, blood glucose; GI, gastrointestinal; HbA_lc, glycated hemoglobin; MUP, multiuse pen; SBP, systolic blood pressure; SUP, single-use pen.